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Abstract
Pulmonary hypertension (PH) increases the work of the right ventricle (RV) and causes
right-sided heart failure. This study examined RV mitochondrial function and ADP transfer in
PH animals advancing to right heart failure, and investigated a potential therapy with the
specific β1-adrenergic-blocker metoprolol. Adult Wistar rats (317 ± 4 g) were injected either
with monocrotaline (MCT, 60 mg kg-1) to induce PH, or with an equivalent volume of saline
for controls (CON). At three weeks post-injection the MCT rats began oral metoprolol (10
mg kg-1 day-1-) or placebo treatment until heart failure was observed in the MCT group. Mito-
chondrial function was then measured using high-resolution respirometry from permeabi-
lised RV fibres. Relative to controls, MCT animals had impaired mitochondrial function but
maintained coupling between myofibrillar ATPases and mitochondria, despite an increase
in ADP diffusion distances. Cardiomyocytes from the RV of MCT rats were enlarged, primar-
ily due to an increase in myofibrillar protein. The ratio of mitochondria per myofilament area
was decreased in both MCT groups (p� 0.05) in comparison to control (CON: 1.03 ± 0.04;
MCT: 0.74 ± 0.04; MCT + BB: 0.74 ± 0.03). This not only implicates impaired energy produc-
tion in PH, but also increases the diffusion distance for metabolites within the MCT cardio-
myocytes, adding an additional hindrance to energy supply. Together, these changes may
limit energy supply in MCT rat hearts, particularly at high cardiac workloads. Metoprolol
treatment did not delay the onset of heart failure symptoms, improve mitochondrial function,
or regress RV hypertrophy.
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Introduction
Pulmonary hypertension (PH) results in right ventricular (RV) hypertrophy and subsequent
right-sided heart failure. The progression of RV hypertrophy to failure in monocrotaline-
induced PH is correlated with mitochondrial dysfunction [1]. Mitochondria are vital for pro-
viding the heart with the energy for contraction and relaxation, supplying up to 95% of the
ATP via oxidative phosphorylation. Previous studies have shown impaired mitochondrial
complex I-fuelled respiration and variable changes in complex II-fuelled respiration in the RV
of rats with PH [1–3]. These studies consistently reported that RV contractile function was sig-
nificantly impaired, particularly at increased workloads, when energy demands are highest.
Structural remodelling of cardiomyocytes that occurs with development of RV hypertrophy
may further impair ADP channelling between the myofibrils and mitochondria, as observed in
failing spontaneously hypertensive rat (SHR) hearts [4]. Impaired transfer of ADP (channel-
ling) in SHR hearts was associated with an increase in mitochondrial reactive oxygen species
(ROS) [4]. Increased mitochondrial ROS production above capacities of oxidative defence sys-
tems is self-damaging, since the ROS producing complexes (namely CI and CIII) of the elec-
tron transfer system (ETS) are also prime targets for oxidative damage [5, 6].
Increased sympathetic nerve activity (SNA) to the heart is characteristic of heart failure,
and is associated with maladaptive cardiac remodelling. Increased SNA is observed in the
form of increased plasma noradrenaline levels and elevated sympathetic nerve activity within
skeletal muscles in PH patients [7, 8]. Although it has been questioned whether these levels
reach clinical significance, a correlation between increased sympathetic nerve activity and clin-
ical deterioration of patients has been observed [9]. β-adrenergic receptor (AR) blockade
forms the basis for successful treatment of left heart failure [10–14]. However, the use of β-AR
blockers in PH patients is thought to be unsafe due to the reliance of the right ventricular out-
put on heart rate and the negative chronotropic effects of β-AR blockers [15]. Despite this,
observational trials of PH patients who receive β-AR blockers for co-morbidity reasons dem-
onstrated the safety of the drugs in this cohort [16, 17]. Promising preclinical experimental evi-
dence for β-AR blocker treatment for right heart failure in rat models of PH is now emerging
[18–22].
We recently demonstrated that the typical positive inotropic response from β-AR stimula-
tion is absent in isolated RV tissue from rats with PH [23]. In addition, β-AR stimulation initi-
ated significant increases in diastolic Ca2+, which would be expected to increase energetic
demand due to futile Ca2+ cycling [23]. Although treatment of heart failure with β-AR blockers
is well established [24], we are not aware of any studies investigating mitochondrial energy
dynamics in β-blocker treated right heart failure.
In the right and left ventricles, β1 and β2-ARs are expressed in a 70:30 ratio [25, 26]. Both
are coupled to the Gs subtype of G-protein coupled receptors (GPCRs) which initiates the
cAMP/PKA signalling pathway [27]. Therefore, acute stimulation of β1-ARs increases the
energy demands of the heart. Chronic stimulation of β1-ARs is associated with harmful pro-
cesses including cell death, fibrosis and remodelling [28]. However, stimulation of β2-ARs,
which can also couple to the Gi subtype, may actually be protective [29, 30]. Metoprolol is a
second generation selective β1-AR blocker, and has been shown to improve survival in rats
with monocrotaline-induced PH, resulting in decreased RV hypertrophy and improved RV
function assessed by echocardiography [22]. Metoprolol was chosen to specifically treat the
failing myocardium, as it has no action on α-AR and β2-AR and no direct effects on the pul-
monary vasculature as seen with e.g. carvedilol [18, 20]. Thus the action of metoprolol is dis-
tinct from current treatment strategies that act to decrease afterload on the RV [15].
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Attenuating β-AR mediated signal transduction (elevated cAMP and PKA activity) is con-
sidered to be the main beneficial effect of β1- and β2-AR blocker treatment, but additional ben-
efits have been found to improve sub-cellular remodelling and oxidative stress (for review see
[14]). Metoprolol treatment in chronic LV heart failure can improve systolic function and
cause regression of hypertrophy on organ [31, 32] and cardiomyocyte levels [33]. It is unclear
whether blocking β1-AR can improve myocardial energy metabolism: it has been shown both
to restore the [CrP]/[ATP] ratio [34, 35], or to have no effect [36] in animal models of heart
failure. Additionally, in a rat model of heart failure, treatment with the β1-AR blocker bisopro-
lol post-myocardial infarction increases cytosolic and mitochondrial creatine kinase (CK)
activities, which should act to improve ATP transfer and buffering within cardiomyocytes
[35].
Cardiac function is reliant on mitochondrial ATP for energy supply which is increased dur-
ing β-adrenergic stimulation. The use of β-blockers might therefore be expected to reduce
energy demands on the heart. However, it is not known if β-blocker treatment with metoprolol
can also improve mitochondrial function and energy transfer in right heart failure. This study
aims to test two hypotheses. (1) That right heart failure induced by PH contributes to an
impairment of mitochondrial function and effective ADP channelling (transfer) between the
myofibrils and mitochondria, and this increases ROS production. (2) That the β1-AR selective
blocker metoprolol treatment can regress right heart failure, improve mitochondrial ADP
channelling, and decrease mitochondrial ROS production. To test these hypotheses, we stud-
ied the monocrotaline (MCT) rat model of PH and right heart failure, along with their age-
matched healthy controls.
Methods
Animal model and metoprolol treatment
PH and RV hypertrophy was induced in male Wistar rats (317 ± 4 g; bred at the University of
Auckland with breeding pairs originally from Charles River Laboratories, USA) by a single
intraperitoneal injection of 60 mg kg-1 monocrotaline in saline (MCT; n = 12). Controls were
injected with an equivalent volume of saline (CON; n = 6). Rats were fed normal rat chow and
water ad libitum for up to six weeks. Rats were monitored (weight gain, water intake and food
consumption) twice weekly for the first two weeks post-injection and then daily once meto-
prolol dosing began. Two days before commencing metoprolol dosing, the rats were trained to
voluntarily ingest sucrose solution (20% (v/v) Ribena and 10% (w/v) sucrose in water) admin-
istered by hand from a 1 ml needleless syringe. At day 20 post-MCT injection, dosing of rats
with metoprolol commenced. Metoprolol tartrate (1.25 mg mL-1; Santa Cruz Biotechnology,
USA) was dissolved in the sucrose solution and administered (10 mg kg-1 day-1) to the treat-
ment group of MCT rats (MCT + BB; n = 6) half an hour before their dark cycle. The dose of
metoprolol used was equivalent to that used by Fowler et al. (2018) [21], but in the present
study dosing commenced at a later stage of development as older animals were used; these
demonstrate a longer time to reach end-stage heart failure based on previous work by our col-
leagues [37]. Remaining MCT and control rats were fed an equivalent volume of the sucrose
solution. In the fourth to fifth week post-injection the MCT and MCT + BB rats were moni-
tored closely for signs of heart failure. Overt signs of heart failure included rats being non-
inquisitive, having hunched posture, lack of grooming, dyspnea, cold/pale extremities, pilo-
erected fur, porphyrin around the eyes and nose, and significant weight loss. Humane end-
points were determined as weight loss of more than: (1) 15% of body weight in 24 hours; (2)
20% of body weight or more plus one other clinical (overt) sign compared with control; or (3)
25% compared with control. All untreated MCT rats were sacrificed when signs of heart failure
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were observed, and MCT + BB rats were sacrificed at a comparable time point. The use of ani-
mals for this study was approved by the University of Auckland Animal Ethics Committee
(reference 001403).
On the day of experimentation, animals were weighed, anaesthetised with isoflurane and
decapitated before excising the heart. The heart was immediately rinsed in ice-cold Tyrode’s
solution prior to blotting and weighing. The wet and dry weights of the liver and lungs were
obtained, as well as the tibial length measurement. During the RV tissue dissection, hearts
were Langendorff-perfused with oxygenated Tyrode’s solution containing (in mM): NaCl
(141.8), KCl (6), MgSO4.H2O (1.2), Na2HPO4 (1.2), 10 HEPES (10), glucose (10), CaCl2 (0.25)
and 2,3-butanedione monoxime (20) at pH 7.4. Approximately 50 mg of tissue was dissected
from the apex of the RV free wall and stored in ice-cold permeabilisation buffer containing (in
mM): CaK2EGTA (2.77; 0.1 μM free Ca2+), imidazole (20), taurine (20), K-MES (4-morpholi-
neethanesulfonic acid; 50), dithiothreitol (0.5), MgCl2 (6.56), ATP (5.77), phosphocreatine
(15) at pH 7.1. Another two samples of the free wall were removed. One sample was snap fro-
zen in liquid nitrogen and stored at -80 ˚C for determination of citrate synthase enzyme activ-
ity and soluble protein content. The other sample was fixed in 1% paraformaldehyde for
confocal imaging. Measurements of the left and right ventricle free wall thickness were
obtained using micro-callipers.
Measurement of mitochondrial respiration in permeabilised muscle fibres
Two assays were performed to assess both the maximum oxidative phosphorylation
(OXPHOS) capacity of the mitochondria in situ (assay 1), as well as the connectivity between
the cytosolic ATPases and the mitochondria within cardiomyocytes (assay 2) [4]. Assays were
performed using an Oroboros-O2k oxygraph (Oroboros Instruments, Austria) with each
chamber equilibrated at 37 ˚C with 2 mL of respiration buffer containing (in mM):
MgCl2.6H2O (3), K-lactobionate (60), taurine (20), KH2PO4 (10), HEPES (20) and sucrose
(110), with essential fatty acid free bovine serum albumin (BSA; 1 g L-1) at pH 7.1. RV tissue
was saponin-permeabilised, as detailed previously [38]. O2 concentration in the chambers was
kept above 350 μM in order to overcome O2 diffusion barriers in the fibres. Steady-state respi-
ration rate was achieved before the titration of each substrate into the chambers.
Assay 1: Exogenously stimulated oxidative phosphorylation. Mitochondrial respiration
was measured from permeabilised fibres in the presence of complex I (CI) substrates glutamate
(10 mM), malate (5 mM) and pyruvate (10 mM), in the absence of ADP. This is known as the
“Leak” state (NADH-stimulated Leak). Maximum CI OXPHOS was stimulated with saturating
MgADP (2.5 mM) [39] followed by the addition of complex II (CII) substrate succinate (10
mM) for combined CI and CII OXPHOS. OXPHOS stimulated with saturating exogenously
added ADP is referred to as OXPHOS.
Assay 2: Endogenously stimulated oxidative phosphorylation with simultaneous mea-
surement of reactive oxygen species. Mitochondrial respiration was measured simulta-
neously with ROS production (Fig 1). ROS were monitored using fluorescent sensors to detect
Amplex UltraRed (AMPR; ThermoFisher Scientific) reagent product Amplex UltroxRed [40].
Approximately 2 mg of permeabilised fibres were added to each oxygraph chamber containing
respiration buffer supplemented with AMPR (5 μM), superoxide dismutase (SOD; 5 U mL-1),
and horse radish peroxidase (HRP; 10 U mL-1). In the presence of SOD, superoxide (O-2.) is
converted to H2O2. The H2O2 produced, along with endogenously produced H2O2, reacts
with AMPR in the presence of HRP to produce the fluorescent product (Amplex UltroxRed)
that represents total ROS production. The signal is calibrated with H2O2 (330 nM) in the
chamber before the addition of permeabilised fibres. CI substrates glutamate (10 mM) and
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malate (5 mM), were added to induce NADH-stimulated Leak. MgATP (2.5 mM) was then
added to measure OXPHOS stimulated by endogenously produced ADP (referred to as ADP-
limited OXPHOS), followed by the addition of CII substrate succinate (10 mM). Phosphoenol-
pyruvate (PEP) was then added as an ‘ADP trap’ to stimulate endogenous ADP scavenger,
pyruvate kinase (PK, Eq 1). Exogenous PK was then titrated (1 U, 1 U, 2 U, 2 U) into the cham-
ber to further scavenge ADP and test the connectivity between the myofibrils and mitochon-
dria [4]. Pyruvate kinase competes with the mitochondria for ADP, therefore, if there is a short
distance between the cytosolic ATPases and mitochondria, then there will be less inhibiton of
respiration with PEP + PK.
ADP þ PEP!PK ATPþ pyruvate ð1Þ
Fig 1. Representative oxygraph trace measuring endogenous OXPHOS and ADP channelling from myofibrils to the mitochondria within
permeabilised fibres. The upper trace shows the O2 concentration (μM; blue) and mass specific O2 flux (pmols s-1 mg-1; red). The lower trace shows
concurrent fluorescent measurement of total ROS (O-2. + H2O2) with enzyme coupled detection system Amplex UltraRed, super oxide dismutase and
horse radish peroxidase. Step wise addition of substrates allows measurement of different respiratory states. Glutamate and malate (GM) produced
NADH-stimulated Leak (CI Leak); ATP stimulates oxidative phosphorylation (OXPHOS) respiration through endogenous production of ADP by
cellular ATPases (CI ADP-limited OXPHOS); succinate is a complex II substrate (CI + CII ADP-limited OXHOS); phosphoenolpyruvate (PEP) is a
substrate for endogenous pyruvate kinase (PK) and a reaction that consumes ADP (ADP trap); additional titration of exogenous PK further tests ADP
channelling towards mitochondria. Finally, addition of creatine stimulates mitochondrial creatine kinase (mCK), promoting local turnover of ADP
within the intermembrane space and relieving inhibition of the ADP trapping enzyme system. Artefacts in the traces (red and green) during the
addition of substrates or O2 have been omitted for clarity.
https://doi.org/10.1371/journal.pone.0214740.g001
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Creatine (10 mM) was then added to the chamber to stimulate localised production of ADP by
mitochondrial creatine kinase within the mitochondrial inter membrane space, which cannot
be accessed by ADP scavenger PK [41]. Following creatine, FCCP was added to uncouple the
mitochondria and measure maximum ETS capacity (ET). Finally, antimycin A (25 μM) was
added to determine background O2 consumption.
Citrate synthase activity and soluble protein content
Citrate synthase and soluble protein content was measured from the frozen RV samples using
colourmetric 96-well plate based assays measured with a Spectramax 340PC plate reader
(Molecular Devices, USA). Tissue was weighed (~20 mg) and homogenised 1:20 (w/v) in
homogenization buffer containing (in mM) EDTA (1), MgCl2 (2), KCl (50), Tris (25) and
0.1% Triton X-100 at pH 7.8. The homogenate was centrifuged at 17,000 x g for 10 minutes.
The supernatant was collected and diluted 5 fold before 5 μL was added to 180 μL of reaction
buffer containing (in mM) acetyl coenzyme A lithium salt (0.1), (5,5’-dithiobis (2-bitrobenzoic
acid) (DTNB; 0.2) and Tris (50) at pH 8.0 in a 96 well plate. The reaction was then started by
the addition of oxaloacetate (0.5 mM) and the production of TNB was followed at 412 nm
[42]. The enzyme activity was normalised to soluble protein content measured using the
bicinchoninic acid method [43].
Immunolabelling and confocal imaging and analysis
Three hearts from each rat group were used for imaging and analysis. RV tissue blocks were
immersion-fixed in 1% paraformaldehyde for 1 hour at 4 ˚C before being cryo-protected with
10, 20 then 30% sucrose in phosphate buffered saline (PBS). The blocks were then frozen in liq-
uid nitrogen, cooled in 2-methylbutane and cryosectioned into 20 μm transversely orientated
sections. Sections were incubated for 1 hour with image iT FX signal enhancer (Life Technolo-
gies) and washed once with PBS for 5 min. Sections were triple labelled for mitochondria
(Tom20), f-actin (phalloidin) and extracellular matrix (wheat germ agglutinin, WGA) as previ-
ously described [4]. The sections were incubated overnight at 4 ˚C with primary antibody rab-
bit anti-Tom20 (1:200, sc-11415, Santa Cruz Biotechnology). Sections were washed before 2
hours of incubation at room temperature with secondary goat anti-rabbit Alexa 488 (1:200,
Thermofisher Scientific) Alexa 594-phalloidin (1:50, Thermofisher Scientific) and Alexa
680-WGA (1:50, Thermofisher Scientific). Sections were washed and mounted in Prolong
Gold (Thermofisher Scientific). Three-dimensional images (0.25 μm spacing, 82 nm pixel size)
were acquired with a Zeiss 710 laser scanning microscope using a Zeiss 63x oil-immersion
objective NA 1.40. Images were deconvolved using the Richardson-Lucy algorithm described
by Soeller and Cannell (1999) [44]. The cross-sectional area of the cardiomyocytes was deter-
mined from the WGA label, and then the densities of mitochondria and f-actin were measured
by creating a mask for each in Fiji (imageJ). The average distance of each pixel to the edge of
the labelled area (mitochondrial clusters or myofibrils) was then calculated using a skeletoniza-
tion and edge-detection script in Python (Version 7.3.2) [4]. Fibrosis was quantified from the
WGA labelling of the extracellular matrix which has been shown previously to be a suitable
method for detection and quantification of fibrosis in cardiac tissue [45].
Data analysis
Measurements of O2 consumption rates and ROS production were recorded in DatLab6 (Oro-
boros Instruments, Austria) for each RV sample. Averaged steady-state data was exported, and
is presented as mean ± SEM for the different respiration states. To infer CI activity, the rate of
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NADH-stimulated OXPHOS was normalised to OXPHOS with succinate (CI OXPHOS/ (CI
+ CII OXPHOS)).
Statistics
Statistical analysis (MCT vs CON vs MCT + BB) was determined by one-way analysis of vari-
ance (ANOVA) followed by Sidak’s multiple comparisons test using Prism 7 (GraphPad Soft-
ware, USA). Differences in ROS production between respiratory states were tested with a
paired t-test.
Chemicals and solutions
Unless otherwise specified, all reagents and chemicals were purchased from Sigma-Aldrich
(USA).
Results
Animal growth and morphometric data
Fig 2 shows the growth trajectory for rats post-monocrotaline or -saline injection. By the fifth
week post-injection, both MCT and MCT + BB rats were significantly lighter than controls
and displayed clinical signs of heart failure. However, while there was a significant drop in
body weight in the MCT rats, and a gain in the control rats between weeks four and five, body
weight tended to plateau in the MCT + BB group. All rats injected with monocrotaline dis-
played overt signs of heart failure by the fifth week, including those treated with metoprolol.
Both the MCT and MCT + BB animals had trends towards greater absolute lung wet
weights compared to controls (CON vs. MCT: p = 0.13; CON vs. MCT + BB: p = 0.058). Both
MCT and MCT + BB rats had increased heart weight and RV hypertrophy relative to controls,
with no change in the LV free wall thickness (Table 1). There was no significant difference in
the liver wet weight or tibial length between groups. None of the morphometric data was
effected by metoprolol treatment, other than the heart:body weight %, which was marginally
lower in the MCT + BB (CON: 0.34 ± 0.01%; MCT: 0.59 ± 0.03%; MCT + BB: 0.51 ± 0.02%;
p� 0.05 for CON vs MCT, CON vs MCT + BB and MCT vs. MCT + BB).
Mitochondrial respiration and ROS production in permeabilised fibres
Mitochondrial respiration was measured in permeabilised fibres stimulated with CI and CII
substrates in the presence of saturating exogenous MgADP (OXPHOS; assay one) or MgATP
which promotes endogenous turnover of ATP to ADP by cytosolic ATPases and subsequent
stimulation of OXPHOS (ADP-limited OXPHOS; assay two).
Assay 1: Exogenously stimulated oxidative phosphorylation. O2 flux was lower in both
the MCT and MCT + BB groups relative to controls in the NADH-stimulated Leak state and
when respiration was measured with saturating MgADP (CI OXPHOS) (Fig 3 & Table 2). Fol-
lowing the addition of complex II substate succinate, O2 flux (CI + CII OXPHOS) remained
lower in the MCT + BB group, but there was only a trend towards significance in the MCT
group (p = 0.07). There was no improvement seen in the MCT + BB group relative to the
MCT group in the OXPHOS states. NADH-stimulated OXPHOS was normalised to CI + CI
OXPHOS to infer CI activity (CI OXPHOS/(CI + CII OXPHOS). In the control fibres NADH
stimulated activity accounted from approximately half of the total flux (CON: 0.51 ± 0.06),
while it only accounted for a third of the total flux in the MCT and MCT + BB fibres (MCT:
0.34 ± 0.02; MCT + BB: 0.35 ± 0.03). Therefore, the contribution of CII activity to overall CI
+ CII OXPHOS is greater in the MCT and MCT + BB hearts.
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Assay 2: Endogenously stimulated oxidative phosphorylation with simultaneous mea-
surement of reactive oxygen species. No difference in O2 flux in the NADH-stimulated
Leak state or following the addition of MgATP (CI ADP-limited OXPHOS) was observed
between groups (Fig 4A). Following, the addition of succinate (CI + CII ADP-limited
OXPHOS), O2 flux was more than 20% lower in the MCT and MCT + BB groups relative to
controls. The addition of the ADP trap (PEP + PK) similarly dropped O2 flux in all groups by
~20% (CON: 19.7 ± 1.6%; MCT: 21.3 ± 2.5%; MCT + BB: 21.9 ± 3%, p = 0.82). Addition of cre-
atine stimulated respiration in all groups by a similar amount (CON: 35 ± 10%; MCT:
Fig 2. Growth trajectory following injection. Mean ± SEM body weight of rats following injection of saline (CON; black; n = 6),
monocrotaline (MCT; grey; n = 5) or monocrotaline plus metoprolol treatment (MCT + BB; red; n = 6). Statistical significance
between CON vs. MCT (�) or CON vs. MCT + BB (#) are denoted by: � p< 0.05; �� or ## p< 0.01; ���� p< 0.0001; using two-way
ANOVA with multiple comparisons and matching. Significant differences between weeks 4 and 5 are denoted by a black � for CON,
and a grey � for MCT.
https://doi.org/10.1371/journal.pone.0214740.g002
Table 1. Morphometric data.
CON MCT MCT + BB p� 0.05
Days post injection 38 ± 4 35 ± 7 32 ± 3 #
Final Body weight (g) 441 ± 12 367 ± 10 395 ± 8 � #
Heart weight (g) 1.49 ± 0.07 2.02 ± 0.17 2.00 ± 0.05 � #
Tibia length (mm)Ɨ 55 ± 1 54 ± 1 51 ± 2
Heart:tibia length (g/cm) Ɨ 0.27 ± 0.01 0.40 ± 0.02 0.39 ± 0.02 � #
Lung weight (g) 1.82 ± 0.11 2.41 ± 0.25 2.62 ± 0.26
Lung:tibia length (g/cm) Ɨ 0.33 ± 0.02 0.47 ± 0.05 0.53 ± 0.07
Liver weight (g) Ɨ 14.9 ± 0.3 13.0 ± 0.6 14.5 ± 1.2
RV free wall (mm) 1.5 ± 0.1 2.7 ± 0.2 2.2 ± 0.1 � #
LV free wall (mm) 4.0 ± 0.1 3.7 ± 0.2 4.1 ± 0.22
Measurements from control (CON; n = 6), monocrotaline (MCT; n = 6, Ɨn = 5), and monocrotaline treated with metoprolol (MCT + BB; n = 6) animals. All data is
expressed as the mean ± SEM except for days post injection which is the median day ± range. Significant differences are denoted by
� p � 0.05 for CON vs. MCT,
# for CON vs. MCT + BB using an ordinary one-way ANOVA with Sidak’s multiple comparisons.
https://doi.org/10.1371/journal.pone.0214740.t001
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30 ± 3%; MCT + BB: 26 ± 4, p = 0.70), and respiration was still ~ 20% lower in the MCT and
MCT + BB groups, relative to controls. The maximum capacity of the ETS measured with
FCCP (ET) was only significantly lower in the MCT + BB group (Table 2). Taken together
these results suggest that there is no detectable change in connectivity between the myofibril
ATPases and the mitochondria that limited OXPHOS.
ROS production was highest for all groups following the addition of succinate (CI + CII
ADP-limited OXPHOS; Figs 1 & 4B). ROS production appeared to be higher in the MCT and
Fig 3. Respiration of permeabilised fibres stimulated with saturating ADP. Mean ± SEM O2 flux normalised to wet
weight (pmol s-1 mg-1) are shown in black for the controls (CON; n = 6), in grey for monocrotaline (MCT; n = 5) and
in red for metoprolol treated monocrotaline rats (MCT + BB; n = 6). Steady-state measurements were taken in the
presence of complex I substrates (CI Leak for NADH-stimulated Leak), after the addition of ADP (CI OXPHOS) and
finally complex II substrate succinate (CI + CII OXPHOS). Statistical significance are denoted by � p< 0.05, ��
p< 0.01, using one-way ANOVA with Sidak’s multiple comparisons.
https://doi.org/10.1371/journal.pone.0214740.g003
Table 2. O2 flux of permeabilised fibres under different respiratory states.
Assay One CON MCT MCT + BB p� 0.05
CI + CII OXPHOS (ADP) (pmols s-1 mg-1) 233 ± 10 191 ± 12 182 ± 12 � #
CI / CI + CII OXPHOS (ADP) 0.51 ± 0.06 0.34 ± 0.02 0.35 ± 0.03 � #
Assay Two CON MCT MCT + BB p� 0.05
CI + CII ADP-limited OXPHOS (ATP) (pmols s-1 mg-1) 207 ± 9 198 ± 24 141 ± 7 # p
CI / CI + CII ADP-limited OXPHOS (ATP) 0.59 ± 0.01 0.52 ± 0.03 0.54 ± 0.02
ET (pmols s-1 mg-1) 294 ± 18 242 ± 32 200 ± 17 #
Mean ± SEM steady-state respiratory states (pmol s-1 mg-1) from control (CON; n = 6), monocrotaline (MCT; n = 5) and metoprolol treated MCT (MCT + BB; n = 6)
permeabilised RV fibres. Respiration was measured with combined CI (glutamate, malate and pyruvate) and CII (succinate) substrates stimulated with either ATP
(ADP-limited OXPHOS) or ADP (OXPHOS). Fractional CI acitivity was determined by normalising CI OXPHOS O2 flux to combined CI + CII OXPHOS (CI / CI
+ CII). The maximum ETS flux (ET) was measured following uncoupling with FCCP (MCT; n = 4).
� p � 0.05 for CON vs. MCT and
# for CON vs. MCT + BB and Ɨ for MCT vs. MCT + BB using an ordinary one-way ANOVA with Sidak’s multiple comparisons.
https://doi.org/10.1371/journal.pone.0214740.t002
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MCT + BB group relative to the control, however, due to large variation in the ROS measure-
ment this was not statistically significant (p = 0.21). Following the addition of phosphoenol-
pyruvate and PK (ADP trap), ROS production dropped in all groups (CON: p = 0.0032; MCT:
p = 0.038; MCT + BB: p = 0.0053). Addition of creatine dropped ROS production further,
however, it was not significant in the MCT group (CON: p = 0.019; MCT: p = 0.105; MCT
+ BB: p = 0.034).
Soluble protein and citrate synthase activity. There was no difference between groups in
the soluble protein content of the tissue (CON: 4.44 ± 0.38%, MCT: 4.75 ± 0.11%, MCT + BB:
Fig 4. O2 flux and ROS production from permeabilised fibres with endogenous ADP. Mean ± SEM measurements are shown in
black for the controls (CON; n = 6), in grey for monocrotaline (MCT; n = 5) and red for metoprolol treated monocrotaline rats
(MCT + BB; n = 5–6). Steady-state measurements were taken during different respiration states outlined in Fig 1. NADH-stimulated
Leak (CI Leak); A: O2 flux normalised to wet weight (pmol s
-1 mg-1). B: Total ROS production normalised to wet weight (pmol s-1
mg-1). Statistical significance between groups are denoted by � p< 0.05, �� p< 0.01 using one-way ANOVA with Sidak’s multiple
comparisons.
https://doi.org/10.1371/journal.pone.0214740.g004
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4.64 ± 0.16%; p = 0.70), or in the citrate synthase activity normalised to soluble protein amount
(CON: 0.031 ± 0.001 μmol min-1 mg-1, MCT: 0.029 ± 0.001 μmol min-1 mg-1, MCT + BB:
0.030 ± 0.003 μmol min-1 mg-1; p = 0.84). Therefore, mitochondrial content measured using
the common citrate synthase marker was not different between groups.
Cardiomyocyte cross-sectional area and mitochondrial and myofibrillar
density
Confocal imaging of RV cardiomyocytes in transverse orientation confirmed cellular hyper-
trophy in MCT groups (Fig 5A). There was an approximate doubling of cardiomyocyte cross-
sectional area with a greater variability in the MCT and MCT + BB hearts relative to controls
(Fig 5C). The MCT and MCT + BB cardiomyocytes also had increased fractional areas occu-
pied by myofilaments, and a decrease in mitochondrial fractional area relative to control cardi-
omyocytes (Fig 5D). The increased myofilament fractional area in the MCT groups was
associated with a decrease in the perimeter/area ratio, and an increased mean pixel and to edge
distance (Fig 5B & Table 3). The smaller mitochondrial fractional area did not correspond to
any changes in the perimeter/area ratio, or to distances to the nearest mitochondrial edge.
When expressed as a fraction of mitochondrial/myofilament area the discrepancy is
highlighted in the MCT and MCT + BB groups (Table 3). Overall, in the MCT hearts, there
was a 25% decrease in the fractional area occupied by mitochondria relative to myofilaments,
with longer diffusion distances between the myofilaments and the mitochondria compared to
control hearts.
Quantification of fibrosis
Since no significant effect of metoprolol was found in the mitochondrial measures, or on RV
myocyte hypertrophy, we examined the degree of fibrosis in the RV tissue as a quality control
for metoprolol efficacy. There was a trend towards an increase in % fibrosis in the MCT group
relative to control (CON: 17 ± 3%; MCT: 32 ± 8%; MCT + BB: 27%; p = 0.07) despite the
apparent decrease in number of cells per unit area (Fig 6).
Discussion
This study examined RV mitochondrial function and ADP channelling in MCT animals
advancing to right heart failure and investigated a potential therapy with the specific β1-AR-
blocker metoprolol. Relative to controls, MCT animals had impaired mitochondrial function
but maintained coupling between myofibrillar ATPases and OXPHOS despite an increase in
fractional myofibrillar content and ADP diffusion distances.
Morphometric animal data and the onset of heart failure
Metoprolol treatment did not delay the onset of overt heart failure symptoms in MCT rats,
although previous studies have shown that metoprolol delays weight loss and prolongs survival
in younger animals with PH [18, 21, 22]. Han et al. (2017) have shown that monocrotaline
injection of 300 g rats leads to a decline of heart function in the fifth week post-injection [37].
We saw significant drop in body weight in the MCT rats between weeks four to five, during
the expected transition from RV hypertrophy to heart failure. Body weight tended to plateau
in the MCT + BB group, suggesting some improvement in the health of the metoprolol treated
rats. However, no regression of RV hypertrophy was evident in the MCT + BB rats (Table 1)
and they still developed overt signs of heart failure. Rats in our study were injected at higher
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Fig 5. Confocal images of RV cardiomyocytes and analysis. A: Representative transverse sections (20 μm) labelled
with extracellular matrix marker (ECM) wheat germ agglutinin (WGA) in blue (first column), mitochondrial marker
anti-Tom20 in green (second row) and f-actin marker phalloidin in red (third row). The final column shows a merged
image of all three channels. Scale bars are 10 μm. Images show RV cardiomyocytes from a control heart (CON; i—iv),
a monocrotaline heart (MCT; v—viii) and a monocrotaline treated with metoprolol heart (MCT + BB; ix—xii). B:
Mask created from image A iii was used to calculate fractional area of f-actin, and determine the mean distance from
the skeleton (B ii) or from each pixel to the outer edge of the f-actin bundles (B iii). Visual representation is shown in
images B ii—iii where all pixels (or skeleton pixels) are coloured according to the distance to their closest edge (white).
C: Cross-sectional area of RV cardiomyocytes determined from tracing the WGA labelling shown in A. D: Fractional
areas calculated from masks created from f-actin (myofilament) and Tom20 (mitochondria) confocal images. Control
(CON; N = 3 hearts, n = 22 cells), monocrotaline (MCT; N = 3 hearts, n = 19 cells) and monocrotaline treated with
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body weight (317 ± 4 g) than those in previous studies (~200 g) [18, 21, 22], and showed a
slower progression to heart failure.
Mitochondrial function in permeabilised RV fibres
There was no apparent benefit of metoprolol treatment in the context of mitochondrial func-
tion. Specific OXPHOS and ETS deficits were investigated by stimulating OXPHOS with the
addition of saturating levels of ADP (Fig 3, and Table 2). Maximal OXPHOS O2 flux was
depressed by ~ 50% in RV fibres from MCT and MCT + BB relative to control when provided
with CI substrates, yet was only ~ 20% lower when provided with CI and CII substrates. This
indicates that the contribution of CI to total OXPHOS is lower in MCT mitochondria at this
time point. Daicho et al. (2009) also found a decrease in CI OXPHOS with the onset of RV
heart failure (MCT induced), with no change in CII OXPHOS measured in permeabilised
fibres [1]. Wust et al. (2016) are in agreement with our finding of depressed OXPHOS medi-
ated by CI substrates, however they also showed depressed CII activity [2]. Taken together
with the findings of our study, a decrease in O2 flux via CI occurs with the onset of right heart
failure, while changes in CII OXPHOS flux are less conclusive. That CII mediated flux can in
part compensate for decreased CI OXPHOS presents a paradox. Succinate, the CII substrate, is
mostly derived from the tricarboxylic acid cycle, which is also forming NADH. NADH in
excess should inhibit the tricarboxylic acid cycle, and be converted to NADPH at a cost of
ATP. Succinate can also be derived from other sources (i.e. glutamate), and if so, would pres-
ent a less efficient means to synthesise ATP [46].
Mitochondrial O2 flux was similarly 20% lower in both MCT and MCT + BB relative to
controls when stimulated by endogenous ADP hydrolysed from ATP by cytosolic ATPases
(Fig 4A). This requires diffusion of ADP from sites of turnover within the cardiomyocytes.
The lower ADP-limited OXPHOS O2 flux (Fig 4A) could result from the longer diffusion dis-
tances between myofibrils and mitochondria (Table 3) in addition to the lower oxidative
capacity of the ETS. Addition of the ADP scavenging ("ADP trap") enzyme system tests the
coupling of the cytosolic ATPases to the mitochondria [4]. The relative drop in O2 flux
metoprolol (MCT + BB; N = 3 hearts, n = 19 cells). Significant differences are denoted by �� p< 0.01, ��� p< 0.001,
���� p< 0.0001, using one-way ANOVA.
https://doi.org/10.1371/journal.pone.0214740.g005
Table 3. Confocal cardiomyocyte sub-cellular measurements.
CON MCT MCT + BB p� 0.05
Myofilament perimeter/area 3.3 ± 0.1 2.7 ± 0.1 2.6 ± 0.1 �#
Mitochondrial perimeter/area 4.1 ± 0.1 4.5 ± 0.2 3.9 ± 0.2
Myofilament skeleton to edge distance (nm) 300 ± 11 365 ± 15 395 ± 19 �#
Myofilament pixel to edge distance (nm) 217 ± 8 270 ± 10 291 ± 14 �#
Mitochondria skeleton to edge distance (nm) 242 ± 6 233 ± 9 253 ± 9
Mitochondria pixel to edge distance (nm) 192 ± 5 194 ± 7 205 ± 7
Mitochondria/myofilament area 1.03 ± 0.04 0.74 ± 0.04 0.74 ± 0.03 �#
Mean ± SEM data calculated from masks created from the f-actin (myofilament) and Tom20 (mitochondria) confocal images as described in Fig 5. Control (CON;
n = 22 cells), monocrotaline (MCT; n = 19 cells) and monocrotaline treated with metoprolol (MCT + BB; n = 19 cells), 3 rat hearts per group.
� p � 0.05 for CON vs. MCT and
# for CON vs. MCT + BB using an ordinary one-way ANOVA with Sidak’s multiple comparisons.
https://doi.org/10.1371/journal.pone.0214740.t003
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following the addition of the ADP trap did not differ between groups (Fig 4A), suggesting that
the increased diffusion distance of 20% is not enough to detect impairing connectivity with
this assay. The MCT RV fibres (from treated and untreated rats) responded to the addition of
creatine with increased O2 flux, however, relative to controls this was still ~ 20% lower in the
MCT and MCT + BB RV fibres (Fig 4A). Mitochondrial creatine kinase expression is
decreased in the RV of MCT animals [47], therefore, cardiomyocytes may become more reli-
ant on ADP channelling for energy transfer within the cytosol.
We measured ROS production in the presence of high ATP, which closely mimics the in
vivo state [4]. No significant difference in ROS production between groups was found, how-
ever, the consequence of CII activity is highlighted in Fig 1 which shows a rapid increase in the
rate of ROS production following the addition of succinate (CI + CII ADP-limited OXPHOS).
This is likely due to superoxide production at CI due to reverse electron transport [48]. The
ADP trap decreased ROS production in all groups following the addition of phosphoenolpyr-
uvate. Phosphoenolpyruvate may have direct ROS scavenging effects [49], and is also con-
verted to pyruvate by endogenous PK [50]. Further addition of exogenous PK with constant
phosphoenolpyruvate concentration resulted in a stepwise increase in ROS production as it
scavenges ADP and inhibits OXPHOS (Fig 1). Creatine decreased ROS production further in
the control and MCT + BB group suggesting that the damaging effects of mitochondrial ROS
are ameliorated by creatine and pyruvate.
Fig 6. Right ventricle fibrosis. A: Representative overview images (248 x 248 μM) of RV tissue labelled with extracellular matrix marker, wheat germ
agglutinin. Five images were taken from each heart (n = 3 hearts). B: Mean ± SEM from control (CON), monocrotaline (MCT) and monocrotaline
treated with metoprolol (MCT + BB). A trend towards significance was found using one-way ANOVA.
https://doi.org/10.1371/journal.pone.0214740.g006
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Mitochondrial content and sub-cellular structural changes
There was no change in citrate synthase activity in the MCT and MCT + BB hearts relative to
controls, despite a decrease in maximum O2 flux. Citrate synthase is often used as a proxy for
mitochondrial content from healthy muscle tissue [51], however, citrate synthase does not cor-
relate with our measurements of mitochondrial fractional area calculated from myocytes.
Mitochondrial area showed a 19% decrease in fractional content in the MCT groups relative to
control (Fig 5D). It is possible that expansion of the myofilaments during hypertrophy com-
pacts mitochondria into a smaller volume, with more densely packed cristae and more concen-
trated citrate synthase. We suggest that citrate synthase activity is not a good marker in states
of disease where overall mitochondrial function may be disconnected from citrate synthase
activity, particularly when the enzyme activity may not reflect the protein expression in dis-
eased hearts [52]. It should be noted that citrate synthase activity was obtained from all cell
types within the myocardial tissue sample, as were the measurements of mitochondrial func-
tion, whereas the mitochondrial area measurements were determined from within cardiomyo-
cytes. While no decrease in connectivity was detected in the mitochondrial respiration assay,
there is clearly an increase in diffusion distances between the myofilaments and mitochondria
determined by the images in Fig 5B. The consequences of the expansion of myofibrils, with no
change in the mitochondrial distances, remains to be resolved (Table 3). The increase in myo-
filament skeleton, or pixel to edge distance, were not decreased by metoprolol treatment.
Metoprolol as a treatment of right heart failure
Although this study did not show a beneficial effect of β1-AR-blocker treatment on mitochon-
drial function in this model of right heart failure, metoprolol treatment requires further inves-
tigation with earlier interventions. We saw body weights plateau from week 4 to week 5 post
injection in MCT + BB, suggesting there could be positive effects if the treatment window was
expanded. β-blocker treatment using bisoprolol has previously been shown to decrease RV
fibrosis in response to monocrotaline induced-PH [19]. We did not find any differences in RV
fibrosis, indexed as wheat germ agglutinin labelling (Fig 6B). However, this method does not
account for differences in myocyte diameter between groups. Studies which use younger ani-
mals with earlier interventions in the MCT rat model show that β1-AR-blocker improves sur-
vival and decreases cardiomyocyte hypertrophy in PH [18, 19, 21]. Previous improvements in
creatine kinase activities and restoration of the [CrP]/[ATP] have been seen after 8 weeks of β-
AR blocker treatment in rats with LV hypertrophy [35]. The MCT rat model has a rapid onset
to heart failure which may not allow time for improvements in mitochondrial function or cre-
atine kinase expression following metoprolol treatment [21]. Reportedly, the third generation
non-selective β-AR blocker carvedilol, may be more effective due to its additional antioxidant
properties [18]. This is reflected in recent randomised clinical trials of patients with PH which
have shown good tolerance and potential cardiac benefits after 6 months of treatment with car-
vedilol [53], whereas there was no improvement following 6 months of selective β1-AR blocker
bisoprolol [54]. However, carvedilol antagonism of β2-AR would prevent any benefits from β2-
AR stimulation [29, 30]. Therefore, a combination of metoprolol and a mitochondrial targeted
antioxidant, such as mito-Q [55], could be more therapeutic with longer dosing time, and war-
rants further investigation.
Conclusion
This study tested two hypotheses, (1) that right-heart failure caused by PH contributes to
impaired mitochondrial function and ADP channeling within the heart, and (2) that metopro-
lol treatment could regress heart failure and ameliorate mitochondrial damage. Our study
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showed significant impairment in RV mitochondrial function in MCT rats due to a decrease
in NADH supplied OXPHOS. This was despite there being an expansion of cardiomyocyte
cross-sectional area, and an increase in fractional myofilament content (Fig 5D), suggesting a
greater need for ATP supply. Our results therefore support the hypothesis that energy deficits
contribute to the contractile dysfunction that leads to right heart failure. However, although
others have reported β-blocker treatment has beneficial effects in monocrotaline-induced RV
dysfunction, we found no evidence here. This raises the question whether β-blocker treatment
in the continued presence of elevated afterload can prevent the progression to right ventricular
failure, particularly when more mature adults are studied.
Supporting information
S1 Table. Table of weekly body weights for each rat used in the study, as shown in Fig 2,
together with group mean ± SEM. The table commences at Week 0 when rats were assigned
to a group, and injected with either 60 mg kg-1 monocrotaline or an equivalent volume of
saline. CON: control, MCT: monocrotaline, MCT + BB: monocrotaline plus ß-blocker. �Note:
MCT 15 was excluded from growth analysis/Fig 2 since it was culled at the end of week 4 due
to significant signs of heart failure.
(PDF)
S2 Table. Table of individual values and group means ± SEM for the respiration of permea-
bilised ventricular fibres stimulated with ADP, as shown graphically in Fig 3.
(PDF)
S3 Table. Table of individual values and group means ± SEM for oxygen flux and ROS pro-
duction from permeabilised ventricular fibres, as shown graphically in Fig 4.
(PDF)
S4 Table. Table of individual values and group means ± SEM of RV myocyte cross-sec-
tional area (μm2), myofilament fractional area (%), and mitochondria fractional area (%),
as shown in Fig 5.
(PDF)
S5 Table. Table of individual values and group means ± SEM of fibrosis determined from
RV tissue labelled with the extracellular matrix marker, wheat germ agglutinin, as shown
in Fig 6.
(PDF)
S6 Table. Table of individual values and group means ± SEM of morphometric data shown
in Table 1.
(PDF)
S7 Table. Table of individual values and group means ± SEM of oxygen fluxes under differ-
ent steady state respiratory states, as shown in Table 2.
(PDF)
S8 Table. Table of individual values and group means ± SEM of cardiomyocyte measure-
ments, as shown in Table 3.
(PDF)
Mitochondrial function remains impaired following metoprolol treatment in a rat model of right heart failure
PLOS ONE | https://doi.org/10.1371/journal.pone.0214740 April 9, 2019 16 / 20
Acknowledgments
We would like to thank Professor Ed White and Associate Professor Sarah Calaghan for pro-
viding feedback during the planning of this project and writing of the manuscript.
Author Contributions
Conceptualization: Ruth Norman, Anthony J. Hickey, Marie-Louise Ward.
Data curation: Amelia S. Power, Timothy L. M. Jones.
Funding acquisition: Marie-Louise Ward.
Investigation: Amelia S. Power, Ruth Norman, Timothy L. M. Jones.
Methodology: Amelia S. Power, Ruth Norman, Anthony J. Hickey.
Project administration: Marie-Louise Ward.
Resources: Marie-Louise Ward.
Supervision: Marie-Louise Ward.
Writing – original draft: Amelia S. Power.
Writing – review & editing: Amelia S. Power, Ruth Norman, Anthony J. Hickey, Marie-Lou-
ise Ward.
References
1. Daicho T, Yagi T, Abe Y, Ohara M, Marunouchi T, Takeo S, et al. Possible involvement of mitochondrial
energy-producing ability in the development of right ventricular failure in monocrotaline-induced pulmo-
nary hypertensive rats. J Pharmacol Sci. 2009; 111(1):33–43. Epub 2009/09/19. PMID: 19763046.
2. Wust RC, de Vries HJ, Wintjes LT, Rodenburg RJ, Niessen HW, Stienen GJ. Mitochondrial complex I
dysfunction and altered NAD(P)H kinetics in rat myocardium in cardiac right ventricular hypertrophy and
failure. Cardiovasc Res. 2016; 111(4):362–72. https://doi.org/10.1093/cvr/cvw176 PMID: 27402402.
3. Redout EM, Wagner MJ, Zuidwijk MJ, Boer C, Musters RJ, van Hardeveld C, et al. Right-ventricular fail-
ure is associated with increased mitochondrial complex II activity and production of reactive oxygen
species. Cardiovasc Res. 2007; 75(4):770–81. Epub 2007/06/22. https://doi.org/10.1016/j.cardiores.
2007.05.012 PMID: 17582388.
4. Power AS, Pham T, Loiselle DS, Crossman D, Ward ML, Hickey AJ. Impaired ADP channeling to mito-
chondria and elevated reactive oxygen species in hypertensive hearts. Am J Physiol Heart Circ Physiol.
2016; 11(310):H1649–H57. Epub 2016/04/17. https://doi.org/10.1152/ajpheart.00050.2016 PMID:
27084386.
5. Choksi KB, Papaconstantinou J. Age-related alterations in oxidatively damaged proteins of mouse
heart mitochondrial electron transport chain complexes. Free Radic Biol Med. 2008; 44(10):1795–805.
https://doi.org/10.1016/j.freeradbiomed.2008.01.032 PMID: 18331850
6. Shao H, Li J, Zhou Y, Ge Z, Fan J, Shao Z, et al. Dose-dependent protective effect of propofol against
mitochondrial dysfunction in ischaemic/reperfused rat heart: role of cardiolipin. Br J Pharmacol. 2008;
153(8):1641–9. https://doi.org/10.1038/bjp.2008.45 PMID: 18311192
7. Velez-Roa S, Ciarka A, Najem B, Vachiery JL, Naeije R, van de Borne P. Increased sympathetic nerve
activity in pulmonary artery hypertension. Circulation. 2004; 110(10):1308–12. https://doi.org/10.1161/
01.CIR.0000140724.90898.D3 PMID: 15337703.
8. Nagaya N, Nishikimi T, Uematsu M, Satoh T, Kyotani S, Sakamaki F, et al. Plasma brain natriuretic pep-
tide as a prognostic indicator in patients with primary pulmonary hypertension. Circulation. 2000; 102
(8):865–70. PMID: 10952954.
9. Ciarka A, Doan V, Velez-Roa S, Naeije R, van de Borne P. Prognostic significance of sympathetic ner-
vous system activation in pulmonary arterial hypertension. Am J Respir Crit Care Med. 2010; 181
(11):1269–75. https://doi.org/10.1164/rccm.200912-1856OC PMID: 20194810.
10. Stephen SA. Unwanted effects of propranolol. Am J Cardiol. 1966; 18(3):463–72. PMID: 4224228.
11. Heilbrunn SM, Shah P, Bristow MR, Valantine HA, Ginsburg R, Fowler MB. Increased beta-receptor
density and improved hemodynamic response to catecholamine stimulation during long-term
Mitochondrial function remains impaired following metoprolol treatment in a rat model of right heart failure
PLOS ONE | https://doi.org/10.1371/journal.pone.0214740 April 9, 2019 17 / 20
metoprolol therapy in heart failure from dilated cardiomyopathy. Circulation. 1989; 79(3):483–90. PMID:
2537158.
12. Eichhorn EJ, Bristow MR. Medical therapy can improve the biological properties of the chronically failing
heart. A new era in the treatment of heart failure. Circulation. 1996; 94(9):2285–96. PMID: 8901684.
13. Dickstein K, Cohen-Solal A, Filippatos G, McMurray JJ, Ponikowski P, Poole-Wilson PA, et al. ESC
Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for
the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardi-
ology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by
the European Society of Intensive Care Medicine (ESICM). Eur Heart J. 2008; 29(19):2388–442.
https://doi.org/10.1093/eurheartj/ehn309 PMID: 18799522.
14. Rehsia NS, Dhalla NS. Mechanisms of the beneficial effects of beta-adrenoceptor antagonists in
congestive heart failure. Exp. Clin. Cardiol. 2010; 15(4):e86–95. PMID: 21264074
15. Galie N, Humbert M, Vachiery JL, Gibbs S, Lang I, Torbicki A, et al. 2015 ESC/ERS Guidelines for the
Diagnosis and Treatment of Pulmonary Hypertension. Revista Espanola de Cardiologia (English ed).
2016; 69(2):177. Epub 2016/02/04. https://doi.org/10.1016/j.rec.2016.01.002 PMID: 26837729.
16. Bandyopadhyay D, Bajaj NS, Zein J, Minai OA, Dweik RA. Outcomes of beta-blocker use in pulmonary
arterial hypertension: a propensity-matched analysis. Eur Respir J. 2015; 46(3):750–60. https://doi.org/
10.1183/09031936.00215514 PMID: 26022959.
17. Grinnan D, Bogaard HJ, Grizzard J, Van Tassell B, Abbate A, DeWilde C, et al. Treatment of group I pul-
monary arterial hypertension with carvedilol is safe. Am J Respir Crit Care Med. 2014; 189(12):1562–4.
https://doi.org/10.1164/rccm.201311-2025LE PMID: 24930531.
18. Bogaard HJ, Natarajan R, Mizuno S, Abbate A, Chang PJ, Chau VQ, et al. Adrenergic receptor block-
ade reverses right heart remodeling and dysfunction in pulmonary hypertensive rats. Am J Respir Crit
Care Med. 2010; 182(5):652–60. https://doi.org/10.1164/rccm.201003-0335OC PMID: 20508210.
19. de Man FS, Handoko ML, van Ballegoij JJ, Schalij I, Bogaards SJ, Postmus PE, et al. Bisoprolol delays
progression towards right heart failure in experimental pulmonary hypertension. Circulation Heart Fail-
ure. 2012; 5(1):97–105. Epub 2011/12/14. https://doi.org/10.1161/CIRCHEARTFAILURE.111.964494
PMID: 22157723.
20. Perros F, Ranchoux B, Izikki M, Bentebbal S, Happe C, Antigny F, et al. Nebivolol for improving endo-
thelial dysfunction, pulmonary vascular remodeling, and right heart function in pulmonary hypertension.
J Am Coll Cardiol. 2015; 65(7):668–80. https://doi.org/10.1016/j.jacc.2014.11.050 PMID: 25677428.
21. Fowler ED, Drinkhill MJ, Stones R, White E. Diastolic dysfunction in pulmonary artery hypertension:
Creatine kinase and the potential therapeutic benefit of beta-blockers. Clin Exp Pharmacol Physiol.
2018;(45):384–9. https://doi.org/10.1111/1440-1681.12898 PMID: 29193283.
22. Fowler ED, Drinkhill MJ, Norman R, Pervolaraki E, Stones R, Steer E, et al. Beta1-adrenoceptor antag-
onist, metoprolol attenuates cardiac myocyte Ca2+ handling dysfunction in rats with pulmonary artery
hypertension. J Mol Cell Cardiol. 2018; 120:74–83. Epub 2018/05/29. https://doi.org/10.1016/j.yjmcc.
2018.05.015 PMID: 29807024
23. Power A, Hickey A, Crossman D, Loiselle D, Ward ML. Calcium mishandling impairs contraction in right
ventricular hypertrophy prior to overt heart failure. Pflugers Arch—Eur J Physiol. 2018; 7(470):1115–26.
24. McMurray JJ, Adamopoulos S, Anker SD, Auricchio A, Bohm M, Dickstein K, et al. ESC Guidelines for
the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis
and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Devel-
oped in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2012; 33
(14):1787–847. https://doi.org/10.1093/eurheartj/ehs104 PMID: 22611136.
25. Brodde OE, Schuler S, Kretsch R, Brinkmann M, Borst HG, Hetzer R, et al. Regional distribution of
beta-adrenoceptors in the human heart: coexistence of functional beta 1- and beta 2-adrenoceptors in
both atria and ventricles in severe congestive cardiomyopathy. J Cardio Pharmacol. 1986; 8(6):1235–
42. PMID: 2434752.
26. Bristow MR, Ginsburg R, Umans V, Fowler M, Minobe W, Rasmussen R, et al. Beta 1- and beta 2-
adrenergic-receptor subpopulations in nonfailing and failing human ventricular myocardium: coupling of
both receptor subtypes to muscle contraction and selective beta 1-receptor down-regulation in heart
failure. Circ Res. 1986; 59(3):297–309. PMID: 2876788.
27. Michel MC, Brodde OE, Insel PA. Are cardiac G-proteins altered in rat models of hypertension? J
Hypertens. 1993; 11(4):355–63. PMID: 8390502.
28. Jensen BC, O’Connell TD, Simpson PC. Alpha-1-adrenergic receptors: targets for agonist drugs to
treat heart failure. J Mol Cell Cardiol. 2011; 51(4):518–28. https://doi.org/10.1016/j.yjmcc.2010.11.014
PMID: 21118696
29. Ahmet I, Morrell C, Lakatta EG, Talan MI. Therapeutic efficacy of a combination of a beta1-adrenore-
ceptor (AR) blocker and beta2-AR agonist in a rat model of postmyocardial infarction dilated heart
Mitochondrial function remains impaired following metoprolol treatment in a rat model of right heart failure
PLOS ONE | https://doi.org/10.1371/journal.pone.0214740 April 9, 2019 18 / 20
failure exceeds that of a beta1-AR blocker plus angiotensin-converting enzyme inhibitor. J Pharmacol
Exp Ther. 2009; 331(1):178–85. https://doi.org/10.1124/jpet.109.157107 PMID: 19587314
30. Xydas S, Kherani AR, Chang JS, Klotz S, Hay I, Mutrie CJ, et al. beta(2)-Adrenergic stimulation attenu-
ates left ventricular remodeling, decreases apoptosis, and improves calcium homeostasis in a rodent
model of ischemic cardiomyopathy. J Pharmacol Exp Ther. 2006; 317(2):553–61. https://doi.org/10.
1124/jpet.105.099432 PMID: 16421285.
31. Hall SA, Cigarroa CG, Marcoux L, Risser RC, Grayburn PA, Eichhorn EJ. Time course of improvement
in left ventricular function, mass and geometry in patients with congestive heart failure treated with beta-
adrenergic blockade. J Am Coll Cardiol. 1995; 25(5):1154–61. PMID: 7897129.
32. Hanada K, Asari K, Saito M, Kawana J, Mita M, Ogata H. Comparison of pharmacodynamics between
carvedilol and metoprolol in rats with isoproterenol-induced cardiac hypertrophy: effects of carvedilol
enantiomers. Eur J Pharmacol. 2008; 589(1–3):194–200. https://doi.org/10.1016/j.ejphar.2008.04.055
PMID: 18534575.
33. Morita H, Suzuki G, Mishima T, Chaudhry PA, Anagnostopoulos PV, Tanhehco EJ, et al. Effects of
long-term monotherapy with metoprolol CR/XL on the progression of left ventricular dysfunction and
remodeling in dogs with chronic heart failure. Cardiovasc Drugs Ther. 2002; 16(5):443–9. PMID:
12652114.
34. Omerovic E, Bollano E, Mobini R, Madhu B, Kujacic V, Soussi B, et al. Selective beta(1)-blockade
improves cardiac bioenergetics and function and decreases neuroendocrine activation in rats during
early postinfarct remodeling. Biochem. Biophys. Res. Commun. 2001; 281(2):491–8. https://doi.org/10.
1006/bbrc.2001.4336 PMID: 11181074.
35. Hugel S, Horn M, de Groot M, Remkes H, Dienesch C, Hu K, et al. Effects of ACE inhibition and beta-
receptor blockade on energy metabolism in rats postmyocardial infarction. Am J Physiol. 1999; 277(6
Pt 2):H2167–75. https://doi.org/10.1152/ajpheart.1999.277.6.H2167 PMID: 10600834.
36. Omerovic E, Bollano E, Soussi B, Waagstein F. Selective beta1-blockade attenuates post-infarct
remodelling without improvement in myocardial energy metabolism and function in rats with heart fail-
ure. Eur J Heart Fail. 2003; 5(6):725–32. PMID: 14675850.
37. Han JC, Guild SJ, Pham T, Nisbet L, Tran K, Taberner AJ, et al. Left-Ventricular Energetics in Pulmo-
nary Arterial Hypertension-Induced Right-Ventricular Hypertrophic Failure. Front Physiol. 2018; 8:1115.
Epub 2018/01/30. https://doi.org/10.3389/fphys.2017.01115 PMID: 29375394
38. Hickey AJ, Chai CC, Choong SY, de Freitas Costa S, Skea GL, Phillips AR, et al. Impaired ATP turnover
and ADP supply depress cardiac mitochondrial respiration and elevate superoxide in nonfailing sponta-
neously hypertensive rat hearts. Am J Physiol Cell. 2009; 297(3):C766–74. Epub 2009/06/26. https://
doi.org/10.1152/ajpcell.00111.2009 PMID: 19553568.
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42. Eigentler A, Draxl A, Wiethüchter A, Kuznetsov A, Lassing B, Gnaiger E. Laboratory protocol: citrate
synthase, a mitochondrial marker enzyme. Mitochond Physiol Network. 2012; 17:1–11.
43. Smith PK, Krohn RI, Hermanson GT, Mallia AK, Gartner FH, Provenzano MD, et al. Measurement of
protein using bicinchoninic acid. Anal Biochem. 1985; 150(1):76–85. PMID: 3843705.
44. Soeller C, Cannell MB. Examination of the transverse tubular system in living cardiac rat myocytes by
2-photon microscopy and digital image–processing techniques. Circ Res. 1999; 84(3):266–75. PMID:
10024300
45. Emde B, Heinen A, Godecke A, Bottermann K. Wheat germ agglutinin staining as a suitable method for
detection and quantification of fibrosis in cardiac tissue after myocardial infarction. Eur J Histochem.
2014; 58(4):2448. Epub 2015/01/13. https://doi.org/10.4081/ejh.2014.2448 PMID: 25578975
46. Hinkle PC. P/O ratios of mitochondrial oxidative phosphorylation. Biochim Biophys Acta. 2005; 1706(1–
2):1–11. https://doi.org/10.1016/j.bbabio.2004.09.004 PMID: 15620362.
47. Fowler ED, Benoist D, Drinkhill MJ, Stones R, Helmes M, Wust RC, et al. Decreased creatine kinase is
linked to diastolic dysfunction in rats with right heart failure induced by pulmonary artery hypertension. J
Mol Cell Cardiol. 2015; 86:1–8. https://doi.org/10.1016/j.yjmcc.2015.06.016 PMID: 26116865
Mitochondrial function remains impaired following metoprolol treatment in a rat model of right heart failure
PLOS ONE | https://doi.org/10.1371/journal.pone.0214740 April 9, 2019 19 / 20
48. Scialo F, Fernandez-Ayala DJ, Sanz A. Role of Mitochondrial Reverse Electron Transport in ROS Sig-
naling: Potential Roles in Health and Disease. Front Physiol. 2017; 8:428. Epub 2017/07/14. https://doi.
org/10.3389/fphys.2017.00428 PMID: 28701960
49. Kondo Y, Ishitsuka Y, Kadowaki D, Fukumoto Y, Miyamoto Y, Irikura M, et al. Phosphoenolpyruvate, a
glycolytic intermediate, as a cytoprotectant and antioxidant in ex-vivo cold-preserved mouse liver: a
potential application for organ preservation. J Pharm Pharmacol. 2013; 65(3):390–401. https://doi.org/
10.1111/j.2042-7158.2012.01602.x PMID: 23356848.
50. Sepp M, Vendelin M, Vija H, Birkedal R. ADP compartmentation analysis reveals coupling between
pyruvate kinase and ATPases in heart muscle. Biophys J. 2010; 98(12):2785–93. https://doi.org/10.
1016/j.bpj.2010.03.025 PMID: 20550890
51. Larsen S, Nielsen J, Hansen CN, Nielsen LB, Wibrand F, Stride N, et al. Biomarkers of mitochondrial
content in skeletal muscle of healthy young human subjects. J Physiol. 2012; 590(14):3349–60. https://
doi.org/10.1113/jphysiol.2012.230185 PMID: 22586215
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